Broad Institute of MIT and Harvard to receive European patent for CRISPR-Cpf1pharmabiz.comCRISPR-Cpf1 holds the potential for simpler and more precise genome engineering than has been available with CRISPR-Cas9. Feng Zhang and collaborators elucidated … Continue reading
|
Celyad to Present at Cowen and Company 37th Annual Health Care Conference
Yahoo Finance The Company utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T–Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, the CAR-T NKR … |
The Denver Post |
Gene therapy to fight a blood cancer succeeds in major study
The Denver Post An experimental gene therapy that turns a patient’s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday. Terminal cancer patients in complete remission after one gene therapy treatmentTelegraph.co.uk Gene Therapy Shows Promise for Aggressive LymphomaEveryday Health (blog) Gene Therapy Study Brings 36 Percent Complete RemissionAmerica Now The Times (subscription) all 98 news articles » |
The Denver Post |
Gene therapy to fight a blood cancer succeeds in major study
The Denver Post An experimental gene therapy that turns a patient’s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday. Terminal cancer patients in complete remission after one gene therapy treatmentTelegraph.co.uk Gene Therapy Shows Promise for Aggressive LymphomaEveryday Health (blog) New gene therapy ‘shrinks tumours like ice cubes’The Times (subscription) America Now all 98 news articles » |
Everyday Health (blog) |
Gene Therapy Shows Promise for Aggressive Lymphoma
Everyday Health (blog) An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy’s developers report. Thirty-six percent of over 100 very ill lymphoma patients appeared disease-free six months … |